Biz Brief: Micromet Stock Rises on Cancer Drug Trial Results

Before you go, we thought you'd like these...
Before you go close icon
Micromet (MITI) shares traded some 3.3% higher on Monday after the small-cap biotech announced that its lead product candidate blinatumomab (MT103) led to remission in almost four-fifths of leukemia patients in a Phase II trial. It also said that a Phase I trial showed the drug induced durable remission in patients with another blood cancer: non-Hodgkin lymphoma.

Micromet is working on immunotherapies -- treatments that aim to trigger the body's own immune system to act against cancer without using toxic chemicals. The company has developed a way to activate T-cells, a type of white blood cells that protect the body against infection, to recognize and attack tumors.

Despite its having no medicines on the market, the 17-year-old company's cancer-fighting technology has attracted attention from large pharmaceuticals. Already, it has signed deals with Bayer (BAYRY), Sanofi-Aventis (SNY), AstraZeneca (AZN), Germany's Merck (MRK) and Boehringer, Bloomberg reports.
Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners

A Holocaust Survivor Found These Old Photographs - And Solved A Decades-Old Mystery A Holocaust Survivor Found These Old Photographs - And Solved A Decades-Old Mystery
Don't Get Too Close To a Newborn Giraffe Unless You Want to Get Kicked in the Nuts Don't Get Too Close To a Newborn Giraffe Unless You Want to Get Kicked in the Nuts
Man Finds 5 Abandoned 'Puppies' In His Garden - Then Quickly Realizes He Made A Big Man Finds 5 Abandoned 'Puppies' In His Garden - Then Quickly Realizes He Made A Big